In primary prevention for patients with familial hypercholesterolemia, with or without DM or MS, the LDL-c target should be < 50 mg/dL, with an indication for a highly potent statin, ezetimibe, and PCSK9 inhibitors until the target is reached. This evidence concerns the gene PCSK9 and diabetes mellitus.